Literature DB >> 3092632

Leu-M1 immunoreactivity in nonhematopoietic neoplasms and myeloproliferative disorders. An immunoperoxidase study of paraffin sections.

G S Pinkus, J W Said.   

Abstract

Leu-M1 is a differentiation antigen present on human myelomonocytic cells, which also has been identified in Reed-Sternberg cells and variants of Hodgkin's disease. This study further defines the tissue distribution of Leu-M1, with immunoreactivity observed for neoplastic cells in 14 of 28 formalin-fixed, paraffin-embedded nonhematopoietic neoplasms. With the use of monoclonal antibodies and an indirect immunoperoxidase technic, Leu-M1 was detected in adenocarcinomas of various sites (breast, lung, colon, thyroid, pancreas, and stomach), in squamous cell and transitional cell carcinomas, and in a small-cell anaplastic carcinoma. Evaluation of a wide variety of myeloproliferative disorders indicated that Leu-M1 effectively characterized mature and immature monocytic cells and myeloid cells at late stages of granulopoiesis, but it was not a reliable marker for early myeloid cells including blasts. Leu-M1 monoclonal antibodies are a useful diagnostic reagent, particularly in the assessment of lymphoproliferative disorders, but must be used with extreme caution and full awareness of its staining profile.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092632     DOI: 10.1093/ajcp/85.3.278

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Bauhinia purpurea--a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30).

Authors:  A B Sarker; T Akagi; H J Jeon; K Miyake; I Murakami; T Yoshino; K Takahashi; S Nose
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

2.  Cytomegalovirus-infected cells express Leu-M1 antigen. A potential source of diagnostic error.

Authors:  J M Rushin; G P Riordan; R B Heaton; R W Sharpe; J D Cotelingam; E S Jaffe
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

3.  Monoclonal antibodies for clinical applications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1988-12       Impact factor: 2.926

4.  Leu-M1 immunoreactivity in the human brain. Discrimination between different tumors and between neoplastic and brain tissue.

Authors:  J Szymas; G Reifenberger; W Wechsler
Journal:  Naturwissenschaften       Date:  1987-04

Review 5.  Value of CD15 immunostaining in diagnosing Hodgkin's disease: a review of published literature.

Authors:  P A Hall; A J D'Ardenne
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

Review 6.  The role of immunocytochemistry in diagnostic pathology.

Authors:  D Y Mason; K C Gatter
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

7.  Severe neuropathy in a patient with acquired immune deficiency syndrome (AIDS). Evidence for widespread cytomegalovirus infection of peripheral nerve and human immunodeficiency virus-like immunoreactivity of anterior horn cells.

Authors:  M E Robert; J J Geraghty; S A Miles; M E Cornford; H V Vinters
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; H Dralle; V Bay; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Monomorphic lymphomas arising in patients with Hodgkin's disease. Correlation of morphologic, immunophenotypic, and molecular genetic findings in 12 cases.

Authors:  T T Casey; J B Cousar; M Mangum; M E Williams; J T Lee; J P Greer; R D Collins
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.